Demant A/S (0RGT) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Demant A/S DKK 99.32, price DKK 313, upside -68.3%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics.
Show more
Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.
Stock analysis
Demant A/S (0RGT) currently trades at kr 312.80, while our model-based Fair Value estimate is kr 99.32, 68.3% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 124.11 per share, and 0 of the 22 models we run sit above the kr 312.80 price.
Bear case: the Asset-Based group reads lowest at kr 25.79, and 22 of the 22 models stay below the price. Evidence for this calculation is medium.
Scenario range: kr 71.79 (bear) to kr 126.85 (bull), the price of kr 312.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Demant A/S reported revenue of 14.5B DKK in FY2020 versus 12.0B DKK in FY2016, a compound +4.8%/yr. Reported net income was 1.1B DKK in FY2020, compounding −6.4%/yr from FY2016.
Key figures
Market cap 67.0B DKK (≈ $10.1B) · P/S ratio 2.92 · Net margin 7.7% · Return on equity 24.2% · Return on assets (EBIT) 11.6% · Operating margin 18.1% · Revenue (TTM) 23.0B DKK · Revenue growth (YoY) +3.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 2% below its 52-week high and 78% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −68%, 0RGT screens richer than that median.
Fair Value models
Bear kr 71.79Fair Value kr 99.32Bull kr 126.85
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−3.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
’16
’17
’18
’19
’20
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.2% (2016) → 10.6% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no share-count history
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Demant A/S Fair Value". https://www.fairvalue-calculator.com/stock/0RGT
Frequently asked questions
Is Demant A/S (0RGT) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of kr 99.32 versus a price of kr 312.80, about −68% upside (overvalued).
What is the fair value of 0RGT?
Our model-based fair value for Demant A/S is kr 99.32 (as of Sep 23, 2026), built from audited fundamentals. The current price: kr 312.80.
What is the quality score of 0RGT?
Demant A/S has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Demant A/S (0RGT)?
Our model-based price target is the fair value of kr 99.32 (as of Sep 23, 2026) from 22 valuation models. Cautious scenario kr 71.79, optimistic scenario kr 126.85. It is a calculation from audited fundamentals, not an analyst target.
What is the Demant A/S stock forecast for 2026?
Our models put fair value at kr 99.32, about −68% upside versus a price of kr 312.80 (overvalued). Cautious scenario kr 71.79, optimistic scenario kr 126.85. The calculation is refreshed regularly with new filings.
What is the revenue of Demant A/S (0RGT)?
Demant A/S reported trailing-twelve-month revenue of about 23.0B DKK (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Demant A/S (0RGT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Demant A/S it is kr 99.32 per share (as of Sep 23, 2026), against a price of kr 312.80. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Demant A/S stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 0RGT trades above its calculated fair value: price kr 312.80, fair value kr 99.32, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0RGT?
No. The price is what the market pays today (kr 312.80); the fair value is what the company's own numbers justify (kr 99.32). For Demant A/S the two are kr 213.48 per share apart. That gap is exactly why we show both numbers side by side.
How much is Demant A/S worth?
The market values Demant A/S at about 67.0B DKK (market capitalisation, as of Sep 23, 2026). Per share that is kr 312.80; our models calculate a fair value of kr 99.32 per share.
What do the bullish and bearish scenarios say about 0RGT?
Our models span a range for Demant A/S: cautious scenario kr 71.79, base kr 99.32, optimistic kr 126.85 per share (as of Sep 23, 2026, price kr 312.80). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0RGT from its 52-week high?
Demant A/S trades at kr 312.80, about 2% below its 52-week high of kr 319.70 and 78% above the low of kr 176.20 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of kr 99.32 is for.
Which stocks are comparable to Demant A/S?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Demant A/S stock attractive at the current price?
The data as of Sep 23, 2026: price kr 312.80, calculated fair value kr 99.32 (−68%), Quality Score 60/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0RGT calculated?
We run Demant A/S through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 99.32, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Demant A/S itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Demant A/S (0RGT)?
The closing price on Oct 2, 2026 was kr 312.80. Our model-based fair value is kr 99.32, about −68% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Demant A/S right now?
The price sits above even our optimistic bull case (kr 126.85). The favourable scenario is already priced in. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Demant A/S
How large is the market capitalisation of Demant A/S (0RGT)?
The market capitalisation of Demant A/S is 67.0B DKK (≈ $10.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Demant A/S (0RGT)?
The price-to-sales ratio of Demant A/S is 2.92 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Demant A/S (0RGT)?
The net margin of Demant A/S is 7.7% (fiscal year 2020). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Demant A/S (0RGT)?
The return on equity (ROE) of Demant A/S is 24.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Demant A/S (0RGT)?
On an EBIT basis the return on assets of Demant A/S is 11.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Demant A/S (0RGT)?
The operating margin of Demant A/S is 18.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Demant A/S (0RGT)?
Revenue at Demant A/S is growing +3.4% versus a year earlier (3y avg +3.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Demant A/S (0RGT)?
Earnings per share at Demant A/S are growing −63.4% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
